MedTrace Logo

Host-pathogen Interactions, Immune Response, and Clinical Prognosis at COVID-19 - the CoVUm Trial

NCT04368013 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 550

Last updated 2023-12-14

No results posted yet for this study

Summary

The project aims to clarify how immunity to SARS-CoV2 develops in humans and to investigate the possibility of finding patients with a particularly effective, neutralizing antibody response for future treatment. The project also aims to detail the virus's damage mechanisms in tissue.

Conditions

Interventions

PROCEDURE

Extended sampling and procedures

The study patients will give additional blood samples and also urine and faeces samples. Spirometry and additional biometric controls will be performed regularly. Necrobiopsies of various organs from deceased patients will be secured and stored for immunohistological and virological analysis.

Sponsors & Collaborators

  • Umeå University

    collaborator OTHER

  • Region Västerbotten

    collaborator OTHER_GOV

  • Örebro University, Sweden

    collaborator OTHER

  • Värmland County Council, Sweden

    collaborator OTHER_GOV

  • Västmanland County Council, Sweden

    collaborator OTHER_GOV

  • Johan Normark

    lead OTHER

Eligibility

Min Age
15 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-28
Primary Completion
2026-04-14
Completion
2026-04-14

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04368013 on ClinicalTrials.gov